Actively Recruiting
Open-label Study of UB-VV400 Gene Therapy with Rapamycin in Patients with Relapsed or Refractory B-cell Malignancies
Led by Umoja Biopharma · Updated on 2026-10-09
274
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying UB-VV400, a gene therapy that creates CD22-targeted CAR T cells inside the body, combined with the drug rapamycin, for patients with relapsed or refractory B-cell malignancies such as large B-cell lymphoma. This Phase 12 study aims to find the best dose and confirm safety and antitumor activity of UB-VV400 in this patient group. Participants will receive a single dose of UB-VV400 followed by treatment with rapamycin. The study includes dose-finding and dose-confirmation phases. The treatments are given sequentially, and the study is open-label, meaning both researchers and participants know what is administered. During the study, participants will be monitored for up to two years to assess safety, tumor response, duration of response, progression-free survival, overall survival, and quality of life. Researchers will collect data on adverse events, pharmacokinetics, and organ function. Visits and assessments will track the effects of the gene therapy and drug combination over time.
CONDITIONS
Brief Title
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
Research Team
L
Luke Walker, MD
C
Christine Dehner
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here